Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
GHRP-66 residuesHWAWFKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone peaks in under 20 minutes. GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic ghrelin mimetic that triggers one of the strongest pituitary GH pulses available from the secretagogue class. Human pharmacokinetic data from Gonzalez and colleagues [1] confirmed a rapid distribution half-life of 7.6 minutes in nine healthy men. The catch: it also floods you with hunger. Ghrelin receptor agonism makes appetite surge roughly 20 minutes after injection, which is either a gift or a problem depending on your goals. Bodybuilders and hard gainers stack it with CJC-1295 No DAC for amplified pulses during bulking phases.
GHRP-6 (Growth Hormone Releasing Peptide-6, CAS 87616-84-0) is a synthetic hexapeptide that binds the growth hormone secretagogue receptor (GHS-R1a) at the pituitary gland. It produces a bigger GH pulse than ipamorelin, but the trade-offs are real. Gonzalez and colleagues characterized its pharmacokinetics in nine healthy male volunteers using IV administration [1], landing on a distribution half-life of 7.6 minutes and an elimination half-life around 2.5 hours. The commonly cited plasma half-life sits at roughly 20 minutes. What separates GHRP-6 from cleaner secretagogues like ipamorelin is its ghrelin mimicry. GHS-R1a is the ghrelin receptor, so agonism there doesn't just release GH. It also triggers orexigenic signaling that makes appetite spike within 20 minutes of injection. Cortisol and prolactin both tick up slightly as well, though these elevations stay mild at standard doses (100 mcg) according to neuroendocrine data from Frieboes and colleagues [2]. Community adoption across thousands of users on r/Peptides and bodybuilding forums has been consistent for over a decade. The top protocol pairs 100 mcg GHRP-6 with 100 mcg CJC-1295 No DAC (Mod GRF 1-29), injected two to three times daily on an empty stomach. Users report improved sleep, faster recovery, and lean mass accrual over 8 to 12 week cycles. No randomized controlled trials exist for body composition outcomes in healthy adults; the evidence base for performance use relies on GH-stimulation data extrapolated through community experience.
GHRP-6 binds the growth hormone secretagogue receptor type 1a (GHS-R1a) on pituitary somatotrophs. Lei and colleagues [3] showed that this binding stimulates phosphatidylinositol turnover, a calcium-dependent intracellular cascade that triggers growth hormone release from secretory granules. The result is a rapid, pulsatile GH spike detectable in serum within 15 to 30 minutes of subcutaneous injection. GHS-R1a is the endogenous ghrelin receptor. GHRP-6 mimics ghrelin's action at this site, which means it doesn't just release GH. It also activates orexigenic (appetite-stimulating) pathways through the hypothalamus. This dual action separates GHRP-6 from more selective GHRPs like ipamorelin, which produce GH pulses without the hunger surge. Beyond GH release, Berlanga-Acosta and colleagues identified a separate receptor pathway through CD36. Their 2017 review [4] and subsequent 2024 cardioprotection study (PMC11169835) demonstrated cytoprotective effects in animal models, including wound healing acceleration [5] and cardiac protection against doxorubicin toxicity. These CD36-mediated effects operate independently of GH signaling. GHRP-6 also produces mild ACTH and cortisol elevation, along with a small prolactin increase. Frieboes and colleagues confirmed these effects in their sleep EEG study [2]. Both elevations remain transient at community doses.
Well-established GH secretagogue via GHS-R1a agonism; also binds CD36 producing cytoprotective effects independent of GH release. Clinical GH-stimulation data is solid (1990s–2000s human trials). Performance/body-composition RCTs do not exist. Cytoprotective evidence is primarily preclinical.
Gonzalez et al. Eur J Pharm Sci 2013 (PMID 23099431): PK/PD in healthy men; Bowers et al. foundational GH-stimulation studies 1980s–1990s; Berlanga et al. Frontiers Pharmacology 2024 (PMC11169835): cardioprotection against doxorubicin in rats
No dose-ranging RCTs for performance/body-composition outcomes in healthy adults. Cytoprotection data is animal models only. Half-life is short (~20 min plasma), requiring frequent dosing. Regulatory status (Category 2 banned from compounding) limits clinical access.
Widely used for mass-gaining protocols due to intense appetite stimulation and strong GH pulse. Often stacked with CJC-1295 No DAC as a GHRH/GHRP pair. Considered the best GHRP for bulking; appetite side effect is treated as a benefit.
Science confirms GHS-R1a agonism and acute GH release in humans. Community protocols extrapolate from mechanism to performance outcomes without RCT support. Appetite stimulation (ghrelin mimicry) is both scientifically validated and community-confirmed. Cycling rationale (receptor desensitization) is mechanistically plausible but not formally studied at community doses.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 200mcg | 2x Daily |
| Aggressive | 300mcg | 3x Daily |
Your first GHRP-6 injection will probably teach you something about hunger you didn't know before. The appetite hit comes fast, usually within 20 minutes, and it's more intense than most people expect. Plan a meal. Reconstitution math for the standard 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg per mL, or 25 mcg per unit on a U-100 insulin syringe. So 100 mcg equals 4 units. 200 mcg equals 8 units. 300 mcg equals 12 units. The thing most beginners miss is the empty stomach requirement. Food within 30 minutes before or after injection substantially blunts the GH pulse. If you eat too close to your dose, you're wasting peptide. Time your injection 30 minutes before a planned meal so the hunger window works in your favor. Store reconstituted vials refrigerated at 2 to 8 degrees Celsius. Use within four weeks. If you see particulates, color changes, or smell anything off after reconstitution, discard the vial.
Continuous GHS-R1a agonism by GHRP-6 leads to receptor downregulation and reduced pituitary sensitivity over time. This is the primary documented mechanism driving cycling protocols. Community reports consistent with mechanistic expectation: hunger response and GH-pulse symptoms typically diminish after 8–12 continuous weeks. A 4–8 week off period allows GHS-R1a density to recover. Antibody formation is theoretically possible with any exogenous peptide but has not been specifically reported as a clinical concern with GHRP-6 at community doses.
Or use the universal Peptide Calculator for any peptide.
Expected: Moderate GH/IGF-1 elevation; pronounced appetite increase; improved sleep depth; visible recovery improvement by week 6
Monitor: Check fasting glucose at baseline and week 6. Check IGF-1 at baseline and week 8.
Aim the stream against the glass wall, not directly onto the powder. Swirl gently until dissolved. This gives you 2,500 mcg per mL.
Draw your dose using a U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle). For 100 mcg, draw to the 4-unit mark. For 200 mcg, draw to the 8-unit mark. For 300 mcg, draw to the 12-unit mark.
Insert the needle at a 45-degree angle into the subcutaneous fat layer. Inject slowly. Release the skin fold and withdraw.
Rotate injection sites with each dose to prevent lipodystrophy. Abdomen and outer thighs are the most common rotation areas.
Inject on an empty stomach with no food 30 minutes before or after the injection. For pre-bed dosing, your last meal should be at least 30 minutes before the shot. For morning dosing, inject fasted and eat your first meal 30 minutes later.
If stacking with CJC-1295 No DAC (Mod GRF 1-29), you can draw both peptides into the same syringe and co-inject. Draw the CJC first, then the GHRP-6.
Refrigerate the reconstituted vial at 2 to 8 degrees Celsius after each use. Use within four weeks of reconstitution.
Reference dose
Inject into abdominal fat or outer thigh. Shorter distribution t½ (7.6 min) than elimination (2.5 h); GH pulse peak at 15–30 min. Rotate sites.
Requires 2–5× higher dose to match SC GH pulse; bioavailability estimates 5–15% intranasal vs. SC
Not common in community practice. Inconsistent absorption; requires nasal spray formulation. Not recommended for primary use.
Destroyed by GI proteases: negligible systemic absorption at standard doses
One 1995 study (PMID 7581965) showed modest GH response to oral GHRP-6 in children at very high doses (300 mcg/kg), not applicable to adult performance dosing. Oral route is not used in practice.
PK study (PMID 23099431) used IV for characterization; SC is standard clinical and community practice
IV was used in pharmacokinetic characterization studies only. Not a practical route for performance use.
Gold-standard GHRH pairing. Acts on GHRH receptor independently of GHS-R1a: true synergy producing amplified GH pulse vs. either alone. Co-inject in same syringe on empty stomach.
100 mcg CJC-1295 No DAC + 100–200 mcg GHRP-6, 2–3×/day
GHRH alternative to CJC-1295 No DAC. Shorter half-life (~12 min) but similar GHRH receptor synergy with GHRP-6. Some users prefer for milder, more physiologic GH pulse.
100–200 mcg sermorelin + 100 mcg GHRP-6, 1–2×/day pre-bed
Long-acting GHRH (half-life ~6–8 days). Provides sustained background GHRH elevation while GHRP-6 generates pulsatile GH spikes. Less pulsatile than No DAC pairing: more blunted but convenient.
1–2 mg CJC-1295 DAC 2×/week + 100–200 mcg GHRP-6 2–3×/day
Competes for the same GHS-R1a receptor. Co-administration provides no additive or synergistic GH benefit: one GHRP displaces the other. Choose one GHRP; stack it with a GHRH instead.
Same GHS-R1a receptor competition: no synergy from combining two GHRPs. If switching GHRPs mid-cycle for receptor variety, use sequentially, not simultaneously.
GHS-R1a competitor. Hexarelin already produces a larger GH pulse than GHRP-6 alone. Combining adds nothing and may increase cortisol/prolactin burden without added GH benefit.
Directly antagonize GH release at the pituitary: will negate GHRP-6 GH-stimulating effect entirely.
Do not combinePricing updated 2026-04-09
The most serious concern with GHRP-6 is its effect on blood glucose regulation. Growth hormone directly opposes insulin action, and GHRP-6 compounds this problem by driving appetite-fueled caloric surpluses that can push fasting glucose upward. Anyone with uncontrolled diabetes, insulin resistance, or prediabetes should treat this as a hard contraindication. Fasting glucose monitoring every four weeks during a cycle isn't optional at this dosing level. Cortisol elevation is the second concern worth weighing carefully. GHRP-6 mildly raises ACTH and cortisol, confirmed by Frieboes and colleagues in their neuroendocrine study [2]. At 100 mcg once daily, this is generally subclinical. At 200 to 300 mcg three times daily, the cumulative cortisol load becomes meaningful enough to potentially impair recovery, sleep quality, and fat metabolism. Users running aggressive protocols should check morning cortisol at week four. Prolactin elevation also occurs, more so than with ipamorelin but less than hexarelin. At aggressive doses, some users report symptoms consistent with raised prolactin. Baseline and week-four prolactin checks are warranted if dosing exceeds 200 mcg per injection. Published side effects from the pharmacokinetic literature include tingling, facial flushing, dizziness, and transient warmth, all of which represent normal GH-pulse effects and typically resolve within 30 to 60 minutes. Community reports confirm these; they're predictable and dose-dependent. Water retention is common at higher doses (200 to 300 mcg range). Users report two to four pounds of water weight during peak dosing weeks. This resolves within one to two weeks of dose reduction or cessation. The appetite effect deserves its own warning. At 300 mcg, hunger becomes genuinely difficult to manage. This is a ghrelin mimetic doing exactly what ghrelin does. Users attempting to use GHRP-6 during a caloric deficit generally abandon the attempt; this peptide is a bulking tool. Injection site reactions (redness, mild irritation) are possible with any subcutaneous peptide. Pregnancy and breastfeeding are absolute contraindications. No human safety data exists for these populations.
Verify GHRP-6 dosing and safety with a second opinion
GHRP-6 is banned from compounding pharmacies (FDA Category 2) as of 2023. All available supply is research-grade from unregulated vendors. Purity varies; vendors quoting ≥99% are not independently verified by FDA oversight. Self-assembly hydrogel research (PMID 41327290) highlights the precision required in formulation: conditions not guaranteed in generic research supply.
| Test | When | Target |
|---|---|---|
| IGF-1 | Baseline, week 6–8, and end of cycle | 250–400 ng/mL (performance context); stay below 500 ng/mL |
| Fasting glucose | Baseline, then every 4 weeks during cycle | <100 mg/dL fasting; flag if >110 mg/dL |
| Morning cortisol | Baseline and week 4 (if using 200–300 mcg doses) | 6–23 mcg/dL (lab dependent) |
| Prolactin | Baseline and week 4 (if using 200–300 mcg doses or experiencing gynecomastia symptoms) | Males: 2–18 ng/mL; flag if >25 ng/mL |
Confirms GH axis is responding; ensures IGF-1 stays in a reasonable range (250–400 ng/mL target for most performance protocols)
GH elevation impairs insulin sensitivity; GHRP-6 appetite stimulation often drives caloric surplus: combined risk for glucose dysregulation
GHRP-6 mildly elevates ACTH/cortisol; at higher doses (especially 3×/day) this may be clinically meaningful
GHRP-6 has mild prolactin-elevating effects vs. ipamorelin; clinically relevant at aggressive dosing
Initial GH pulses detectable within 15-30 minutes of injection. Intense hunger onset ~20 minutes post-dose. Possible tingling, dizziness, or flushing at injection site.
Appetite increase becomes predictable and pronounced. Sleep quality begins to improve, especially with evening dosing. Mild water retention may appear.
Cumulative GH elevation supports noticeable recovery improvements. Body composition shifts begin: increased lean mass, reduced fat. Hunger effects stabilize as users adapt meal timing around doses.
Full benefits realized: improved muscle fullness, faster recovery, deeper sleep. Cortisol and prolactin elevations remain mild and transient at standard doses. Consider cycling off after 8-12 weeks to prevent receptor desensitization.
Days 1 to 3: GH pulses show up fast. Peak serum growth hormone hits within 15 to 30 minutes of your first subcutaneous injection, confirmed by Gonzalez PK data [1]. Hunger kicks in around the 20-minute mark and it's not subtle. Tingling in the hands and feet, warm flushing across the face, and mild dizziness are all normal GH-pulse indicators. Most users notice deeper sleep on the very first night if dosing pre-bed. Weeks 1 to 2: The hunger response locks into a predictable pattern. You'll know exactly when it hits and how long it lasts, which makes meal timing straightforward. Sleep quality improvement becomes consistent, especially with evening dosing. Expect one to two pounds of mild water retention. Energy and training capacity start trending upward. Weeks 3 to 6: Body composition shifts become visible. Lean mass gains are noticeable; recovery between training sessions gets measurably faster. Strength gains vary by individual. Fat loss is generally blunted because the appetite effect drives caloric surpluses, this is a bulking tool by design. Some users report improved skin quality during this window. Water retention can peak at two to four pounds. Weeks 6 to 12: Full benefits are on display. Muscle fullness, fast recovery, deep sleep. The hunger response may moderate slightly as your body adapts. By week 10 to 12, some users notice the GH-pulse sensations (tingling, flushing) starting to fade. That's GHS-R1a desensitization setting in, and it's the signal to cycle off for four to six weeks before your next run.
Peak GH within 15–30 min of injection (Gonzalez PK data). Ghrelin-receptor agonism triggers orexigenic signal within ~20 min.
Immediate and intense hunger ~20–30 min post-injection. Tingling in hands/feet, warm flushing, mild dizziness: typical GH-pulse effects. Sleep feels deeper on night-time dose within first few nights.
Repeated pulsatile GH stimulation; early IGF-1 elevation emerging. Ghrelin signaling upregulates appetite consistently.
Hunger response becomes very predictable: users learn to time meals. Sleep quality improves noticeably, especially with pre-bed dosing. Mild water retention begins. Energy and training capacity trending up.
Sustained IGF-1 elevation supports anabolic signaling. GH-mediated lipolysis may begin competing with appetite-driven caloric surplus.
Visible lean mass gains. Recovery between sessions noticeably faster. Strength gains, though variable. Fat loss blunted by caloric surplus from appetite stimulation: this is a bulking tool, not a cut tool. Some users report skin quality improvements.
Maximal IGF-1 and body composition response achievable with this peptide class. GHS-R1a downregulation begins to emerge with continuous daily use beyond this window.
Full muscle fullness, improved body composition, deep sleep, fast recovery. Hunger response may slightly moderate as users adapt. Some report beginning of diminished GH-pulse sensation by week 10–12: cycling off recommended at this stage.
Source: Gonzalez et al. Eur J Pharm Sci 2013 (PMID 23099431): distribution t½ 7.6 min, elimination t½ ~2.5 h; commonly cited plasma t½ ~20 min
Loading the interactive decay curve.
GHRP-6 is not FDA-approved for any medical indication. It is classified as a research chemical in the United States. In 2023, the FDA placed GHRP-6 on the Category 2 list, which bans it from compounding pharmacies. All supply currently available comes from unregulated research peptide vendors. For athletes, GHRP-6 is prohibited by the World Anti-Doping Agency (WADA) under the category of growth hormone secretagogues. It is banned both in-competition and out-of-competition. Regulatory status varies by country. In most jurisdictions, purchasing GHRP-6 labeled "for research purposes only" occupies a legal gray area. It cannot legally be marketed or sold for human consumption. This content is provided for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide or research compound.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
